1. Nicola NA, Metcalf D, Matsumoto M, Johnson GR. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem 1983; 258:9017-9023.

2. Welte K, Platzer E, Lu L, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985; 82:1526-1530.

3. Nomura H, Imazeki I, Oheda M, et al. Purification and characterization of human granulocyte colony-stimulating factor (G-CSF). EMBO J 1986; 5:871-876.

4. Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986; 319:415-418.

5. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232:61-65.

6. Flynn J, Salvado AJ, Foote MA. Hematopoietic growth factors. In: Crommelin DJA, Sindelar RD, eds., Pharmaceutical Biotechnology. London: Harwood Academic. 193-215, 2002.

7. Kanda N, Fukushige S, Murotsu T, et al. Human gene coding for granulocyte-colony stimulating factor is assigned to the q21-q22 region of chromosome 17. Somat Cell Mol Genet 1987; 13:679-684.

8. Koeffler HP, Gasson J, Ranyard J, Souza L, Shepard M, Munker R. Recombinant human TNF alpha stimulates production of granulocyte colony-stimulating factor. Blood 1987; 70:55-59.

9. Ernst TJ, Ritchie AR, Demetri GD, Griffin JD. Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcrip-tional level. J Biol Chem 1989; 264:5700-5703.

10. Nishizawa M, Nagata S. Regulatory elements responsible for inducible expression of the granulocyte colony-stimulating factor gene in macrophages. Mol Cell Biol 1990; 10:2002-2011.

11. Platzer E, Oez S, Welte K, et al. Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. Immunobiology 1986; 172:185-193.

12. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56:809-813.

13. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neu-tropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothe-lium. N Engl J Med 1988; 318:1414-1422.

14. Gabrilove JL, Jakubowski A, Fain K, et al. Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 1988; 82:1454-1461.

15. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1:667-672.

16. Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88:1907-1929.

17. Kubota N, Orita T, Hattori K, Oh-eda M, Ochi N, Yamazaki T. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem 1990; 107:486-492.

18. Zink T, Ross A, Luers K, Cieslar C, Rudolph R, Holak TA. Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy: loop mobility in a four-helix-bundle protein. Biochemistry 1994; 33:8453-8463.

19. Oh-eda M, Hasegawa M, Hattori K, et al. O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J Biol Chem 1990; 265:11432-11435.

20. Ono M. Physicochemical and biochemical characteristics of glycosylated recombinant human granu-locyte colony stimulating factor (lenograstim). Eur J Cancer 1994; 30A(suppl 3):S7-11.

21. Wang C, Eufemi M, Turano C, Giartosio A. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 1996; 35:7299-7307.

22. Arakawa T, Prestrelski SJ, Narhi LO, Boone TC, Kenney WC. Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J Protein Chem 1993; 12:525-531.

23. Nissen C. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur J Cancer 1994; 30A(suppl 3):S12-14.

24. Pedrazzoli P, Gibelli N, Pavesi L, et al. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res 1996; 16:1781-1785.

25. Mire-Sluis AR, Das RG, Thorpe R. The international standard for granulocyte colony stimulating factor (G-CSF). Evaluation in an international collaborative study. Participants of the Collaborative Study. J Immunol Methods 1995; 179:117-126.

26. Querol S, Cancelas JA, Amat L, Capmany G, Garcia J. Effect of glycosylation of recombinant human granulocytic colony-stimulating factor on expansion cultures of umbilical cord blood CD34+ cells. Haematologica 1999; 84:493-498.

27. Tanaka H, Tanaka Y, Shinagawa K, Yamagishi Y, Ohtaki K, Asano K. Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine 1997; 9:360-369.

28. Bonig H, Silbermann S, Weller S, et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF)—results of a prospective randomised monocentre study. Bone Marrow Transplant 2001; 28:259-264.

29. Nohynek GJ, Plard JP, Wells MY, Zerial A, Roquet F. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and non-neutropenic CD rats. Cancer Chemother Pharmacol 1997; 39:259-266.

30. Uzumaki H, Okabe T, Sasaki N, et al. Identification and characterization of receptors for granulocyte colony-stimulating factor on human placenta and trophoblastic cells. Proc Natl Acad Sci USA 1989; 86:9323-9326.

31. Piao YF, Okabe T. Receptor binding of human granulocyte colony-stimulating factor to the blast cells of myeloid leukemia. Cancer Res 1990; 50:1671-1674.

32. Okabe M, Asano M, Kuga T, et al. In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor. Blood 1990; 75:1788-1793.

33. Togawa A, Mizoguchi H, Toyama K, Urabe A, Ohasi Y, Takaku F. [Clinical evaluation of rhG-CSF in patients with neutropenia induced by chemotherapy for multiple myeloma]. Rinsho Ketsueki J Clin Hematol 2000; 41:115-122.

34. Hangzhou Jiuyuan Gene Engineering Co, Ltd.; accessed 18 September 2002.

35. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002; 54:459-476.

36. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C. Mono-N-terminal poly(ethylene glycol)-pro-tein conjugates. Adv Drug Deliv Rev 2002; 54:477-485.

37. Hinds KD, Kim SW. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 2002; 54:505-530.

38. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 2002; 54:531-545.

39. Wang Y-S, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002; 54:547-570.

40. Veronese FM, Caliceti P, Schiavon O, Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 2002; 54:587-606.

41. Molineux G. Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treat Rev 2002a; 28(Suppl A):13-16.

42. Eliason JF, Greway A, Tare N, et al. Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol. Stem Cells 2000; 18:40-45.

43. Tanaka H, Satake-Ishikawa R, Ishidawa M, Matsuki S, Asano K. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor conjugated to polyethylene glycol in rats. Cancer Res 1991; 51:3710-3714.

44. van Der Auwera P, Platzer E, Xu ZX, et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol 2001; 66:245-251.

45. van Spriel AB, van den Herik-Oudijk IE, van de Winkel JG. A single injection of polyethylene-glycol granulocyte colony-stimulating factor strongly prolongs survival of mice with systemic candidiasis. Cytokine 2000; 12:666-670.

46. Jensen-Pippo KE, Whitcomb KL, Deprince RB, Ralph L, Habberfield AD. Internal bioavailability of human granulocyte colony stimulating factor conjugated with poly(ethylene glycol). Pharm Res 1996; 13:102-107.

47. Molineux G, Kinstler O, Briddell B, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27:1724-1734.

48. de Haan G, Ausema A, Wilkens M, Molineux G, Dontje B. Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes. Br J Haematol 2000; 110:638-646.

49. Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res 2001; 7:2085-2090.

50. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13:903-909.

51. Green M, Koelbl H, Baselga J, et al. A randomized, double-blind, phase III study of fixed-dose, singleadministration pegfilgrastim vs daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14:29-35.

52. Yowell SL, Crawford J, Holmes FA, Yang B, Liang BC. Sustained-duration, once-per-chemotherapy-cycle pegfilgrastim demonstrates highly efficient, self-regulating, neutrophil-dependent elimination. Pharmacotherapy 2001; 21:1281.

53. Niven RW, Prestrelski SJ, Treuheit MJ, Ip AY, Arakawa T. Protein nebulization II. Stabilization of G-CSF to air-jet nebulization and the role of protectants. Int J Pharmaceutics (Amsterdam) 1996; 127:191-201.

54. Watanabe Y, Kiriyama M, Oe J, Kikuchi R, Mizufune Y, Matsumoto M. Pharmacodynamic activity (leukopoietic effect) of recombinant human granulocyte colony-stimulating factor (rhG-CSF) after rectal administration in rabbits with leukopenia induced by cyclophosphamide. Biol Pharm Bull 1996; 19:1064-1067.

55. Kojima S, Matsuyama T, Kodera Y, et al. Measurement of endogenous plasma granulocyte colony-stimulating factor in patients with acquired aplastic anemia by a sensitive chemiluminescent immunoassay. Blood 1996; 87:1303-1308.

56. Cebon J, Layton JE, Maher D, Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol 1994; 86:265-274.

57. Umesaki N, Fukumasu H, Miyama M, Kawabata M, Ogita S. Plasma granulocyte colony stimulating factor concentrations in pregnant women. Gynecol Obstet Invest 1995; 40:5-7.

58. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84:1737-1746.

59. Coccia MA, Hartley C, Sutherland W, et al. Prolonged neutropenia in a novel mouse granulocyte colony-stimulating factor neutralizing auto-immunoglobulin G mouse model. Exp Hematol 2001; 29 59-67.

60. Liu F, Wu HY, Wesselschmidt R, Kornaga T, Link DC. Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity 1996; 5:491-501.

61. Lord BI. Myeloid cell kinetics in response to haemopoietic growth factors. Baillieres Clin Haematol 1992; 5:533-550.

62. Lord BI, Molineux G, Pojda Z, Souza LM, Mermod JJ, Dexter TM. Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood 1991; 77:2154-2159.

63. Morstyn G, Campbell L, Lieschke G, et al. Treatment of chemotherapy-induced neutropenia by sub-cutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 1989; 7:1554-1562.

64. Di Leo A, Bajetta E, Nole F, et al. The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study. Br J Cancer 1994; 69:961-966.

65. Tanaka H, Tokiwa T. Pharmacokinetics of recombinant human granulocyte colony-stimulating factor studied in the rat by a sandwich enzyme-linked immunosorbent assay J Pharmacol Exp Ther 1990; 255:724-729.

66. Tanaka H, Kaneko T. Pharmacokinetic and pharmacodynamic comparisons between human granulo-cyte colony-stimulating factor purified from human bladder carcinoma cell line 5637 culture medium and recombinant human granulocyte colony-stimulating factor produced in Escherichia coli. J Pharmacol Exp Ther 1992; 262:439-444.

67. Kearns CM, Wang WC, Stute N, Ihle JN, Evans WE. Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. J Pediatr 1993; 123:471-479.

68. Nichol JL, Hokom MM, Hornkohl A, et al. Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995; 95:2973-2978.

69. Marsh JC, Gibson FM, Prue RL, et al. Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 1996; 95:605-610.

70. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocy-topenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87:4068-4071.

71. Fielder PJ, Hass P, Nagel M, et al. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89:2782-2788.

72. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 1997; 283:520-527.

73. Redman BG, Flaherty L, Chou TH, et al. Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. J Immunother 1992; 12:50-54.

74. Bauer RJ, Gibbons JA, Bell DP, Luo ZP, Young JD. Nonlinear pharmacokinetics of recombinant human macrophage colony-stimulating factor (M-CSF) in rats. J Pharmacol Exp Ther 1994; 268:152-158.

75. Layton JE, Hockman H, Sheridan WP, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989; 74:1303-1307.

76. Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 1992; 79:2849-2854.

77. Shimazaki C, Uchiyama H, Fujita N, et al. Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation. Exp Hematol 1995; 23:1497-1502.

78. Takatani H, Soda H, Fukuda M, et al. Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts. Antimicrob Agents Chemother 1996; 40:988-991.

79. Sturgill MG, Huhn RD, Drachtman RA, Ettinger AG, Ettinger LJ. Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelo-suppressive cancer chemotherapy: clearance increases in relation to absolute neutrophil count with repeated dosing. Am J Hematol 1997; 54:124-130.

80. Kuwabara T, Uchimura T, Kobayashi H, Kobayashi S, Sugiyama Y. Receptor-mediated clearance of G-CSF derivative nartograstim in bone marrow of rats. Am J Physiol 1995; 269:1-9.

81. Kuwabara T, Uchimura T, Takai K, Kobayashi H, Kobayashi S, Sugiyama Y. Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo. JPharmaco Exp Ther 1995; 273:1114-1122.

82. Kuwabara T, Kobayashi S, Sugiyama Y. Kinetic analysis of receptor-mediated endocytosis of G-CSF derivative, nartograstim, in rat bone marrow cells. Am J Physiol 1996; 271:1-84.

83. Tanaka H, Tokiwa T. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor krn-8601 in the rat. Cancer Res 1990; 50:6615-6619.

84. Kuwabara T, Ishikawa Y, Kobayashi H, Kobayashi S, Sugiyama Y. Renal clearance of a recombinant granulocyte colony-stimulating factor, nartograstim, in rats. Pharm Res 1995; 12:1466-1469.

85. Fukuda M, Oka M, Ishida Y, et al. Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients. Antimicrob Agents Chemother 2001; 45:1947-1951.

86. Schwab G, Roskos L, Molineux G, et al. A phase I study of sustained-duration filgrastim in normal volunteers. Exp Hematol 1998; 26:709.

87. Roskos LK, Yang B, Schwab G, et al. A cytokinetic model describes the granulopoietic effects of r-metHuG-CSF-SD/01 (SD/01) and the homeostatic regulation of SD/01 clearance in normal volunteers. Clin Pharmacol Ther 1999; 65:196.

88. Morstyn G, Dexter TM, Foote MA, eds. Filgrastim (r-metHuG-CSF) in Clinical Practice, 2nd ed. Totowa, NJ: Humana. 1998.

89. Gratwohl A, Hermans J, Baldomero H. Blood and marrow transplantation activity in Europe 1995. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19:407-419.

90. Tyndall A. Immunoablation and haemopoietic stem cell transplantation for severe autoimmune disease with special reference to systemic lupus erythematosus. Lupus 2001; 10:214-215.

91. Wulf GG, Jackson KA, Goodell MA. Somatic stem cell plasticity: current evidence and emerging concepts. Exp Hematol 2001; 29:1361-1370.

92. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001; 98:10344-10349.

93. Korzenik JR, Dieckgraefe BK. Immunostimulation in Crohn's disease: results of a pilot study of G-CSF (R-methuG-CSF) in mucosal and fistulizing Crohn's disease. Gastroenterology 2000; 118:AGA A874-AGA A875.

94. Dejaco C, Gasche C, Poetzi R, Gangl A, Vogelsang H, Reinisch W. Safety and efficacy of granulocyte colony stimulating factor (G-CSF) for treatment of severe endoscopic postoperative recurrence in Crohn's disease (CD). Gastroenterology 2000; 118:AGA A566.

95. Edmonds M, Gough A, Solovera J, Standaert B. Filgrastim in the treatment of infected diabetic foot ulcers. Retrospective cost analysis of a phase II randomised clinical trial. Clin Drug Invest 1999; 17:275-286.

96. Froberg MK, Garg UC, Stroncek DF, Geis M, McCullough J, Brown DM. Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving gran-ulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection. Transfusion 1999; 39:410-414.

97. Kubista E, Glaspy J. Holmes FA, et al. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 2003; 3:391-398.

98. Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000; 96:429-436.

99. Tschan CA, Pilz C, Zeidler C, Welte K, Germeshausen M. Time course of increasing numbers of mutations in the granulocyte colony-stimulating factor receptor gene in a patient with congenital neu-tropenia who developed leukemia. Blood 2001; 97:82-1884.

100. Bishop NJ, Williams BM, Compston JC, Stirling DM, Prentice A. Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor. Br J Haematol 1995; 89:927-928.

101. Simon M, Lengfelder E, Reiter S, Hehlmann R. Osteoporosis in severe congenital neutropenia: Inherent to the disease or a sequela of G-CSF treatment? Am J Hematol 1996; 52:127.

The Smoker's Sanctuary

The Smoker's Sanctuary

Save Your Lungs And Never Have To Spend A Single Cent Of Ciggies Ever Again. According to a recent report from the U.S. government. Centers for Disease Control and Prevention, more than twenty percent of male and female adults in the U.S. smoke cigarettes, while more than eighty percent of them light up a cigarette daily.

Get My Free Ebook

Post a comment